Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Study Overview: Amgen Inc. is conducting a clinical ...

H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted the biologics license ...

The addition of an investigational therapeutic cancer vaccine to first-line pembrolizumab exhibited activity among patients ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives ...

Overall survival was significantly better with the combination therapy, achieving 23.1 months versus 19.6 months with PHP alone. Combination therapy of percutaneous hepatic perfusion with immune ...

Safety results showed no increase in immune-mediated adverse events (34.0% vs 38.4%) or treatment-related adverse events ...

Nanobiotix S.A. has surged on strong NBTXR3 data, but its sole asset is out-licensed to Johnson & Johnson. Learn more about ...

Bristol-Myers Squibb Company has had a recent 30% stock decline amid concerns over patent expirations. Click here to read why BMY stock is a Hold.